News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Announces Data Presentations For EPIT At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2014


3/25/2014 9:34:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BAGNEUX, France, March 25, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of ViaskinĀ®, a new paradigm for the treatment of allergies, announced today that five scientific presentations of data related to its proprietary method, Epicutaneous Immunotherapy (EPITTM), have been selected with four as oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014 held in Copenhagen, Denmark, June 7-11.The abstracts will also be published in the June 2014 supplement of Allergy.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES